News & Views
Siemens Healthineers Announces Bengaluru Innovation Hub Investment
Oct 27 2020
Siemens Healthineers has announced plans to invest €160 million over the next five years in an innovation hub in Bengaluru, India. The innovation hub will be housed in a new state-of-the-art campus that combines the existing R&D centre and an ultra-modern medical imaging factory. To expand its digital capabilities, the company plans to add up to 1,800 digital talents in the next ten years. The investment is part of Siemens Healthineers’ strategy 2025, in which India plays an important role as a growth market for the company.
“This investment is the largest we have ever made in India. It will play a key role in taking our business to the next level by driving digitalisation and expanding our portfolio for emerging markets. The innovation hub in Bengaluru will demonstrate our commitment to advance healthcare through cutting-edge digital technologies as well as through accessible and affordable innovations driven from India,” said Elisabeth Staudinger, President Asia Pacific, Siemens Healthineers.
Explaining the Siemens Healthineers innovation hub concept, Peter Schardt, the company’s Chief Technology Officer, pointed out that: “The innovation hub in Bengaluru is an integral part of our global network of innovation that will further accelerate our ability to develop effective solutions quickly and with a strong focus on emerging markets, especially in Asia. The Bengaluru innovation hub will assume increased responsibility for customer centric solutions to serve such markets even better. Special focus is on solutions for the digitalisation of healthcare, which is the foundation for value-based and patient-centered medicine within the region and across the globe.”
So far, Siemens Healthineers has already invested about €300 million in R&D in the country. With about 50% of all the software engineers in Siemens Healthineers, the existing R&D centre at Bengaluru plays a strategic role in developing cutting-edge software products and platforms for all three segments of the company - Imaging, Diagnostics, and Advanced Therapies.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark